Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
23.21
+1.29 (5.89%)
Aug 13, 2025, 4:00 PM - Market closed
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $1.30M in the quarter ending June 30, 2025, with 1,200.00% growth. This brings the company's revenue in the last twelve months to $1.40M, down -24.45% year-over-year. In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$1.40M
Revenue Growth
-24.45%
P/S Ratio
260.48
Revenue / Employee
$8,696
Employees
161
Market Cap
335.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
Dec 31, 2022 | 1.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 17 hours ago - Inhibrx Reports Second Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Inhibrx Reports First Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PRNewsWire
- 5 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - PRNewsWire
- 7 months ago - Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PRNewsWire
- 7 months ago - Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PRNewsWire
- 9 months ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 10 months ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha